Empowered Patient Podcast

Venkat Nelabhotla, Chief Executive Officer, Vyome Therapeutics discusses the growing problem of antimicrobial resistance in medicine and how Vyome is working to tackle resistant dermatological conditions using their understanding of the skin microbiome.  Focusing first on acne, Vyome is developing VB-1953, a topical gel capable of killing resistant strains of P. acnes to help deliver solutions to the more than 10 million patients in the US, and more world-wide, with antibiotic resistant acne. @vyometx Vyome Therapeutics